Details werden geladen...
A standing ovation for RevMed, and caution for Akeso | STAT
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
Ähnliche Seiten
Revolution Medicines starts early access for pancreatic cancer drug | STAT
https://www.statnews.com/2026/05/30/pancreatic-cancer-daraxonrasib-revolution-medicines-early-access-asco-2026/An ASCO preview: What to watch for at cancer research's big meeting | STAT
https://www.statnews.com/2026/05/28/asco-preview-cancer-meeting/BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
https://www.statnews.com/2026/05/30/asco-news-day-2-biontech-pfizer-kelun-merck-pazdur/At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways
https://www.statnews.com/2026/06/01/asco-news-day-4-merkel-cell-carcinoma-glp1s-grail/At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
https://www.statnews.com/2026/05/29/asco-news-day-1-multiple-myeloma-bristol-lung-cancer-pfizer/